FPH provides ASX CEO Connect presentation

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Fisher & Paykel Healthcare provides ASX CEO Connect presentation

Auckland, New Zealand, 20 June 2023 - Fisher & Paykel Healthcare Corporation Limited attaches
a copy of its presentation for the ASX’s CEO Connect webinar to be held later today.

There is no new material information contained within the presentation.

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive
sleep apnea. The company’s products are sold in over 120 countries worldwide. For more
information about the company, visit our website www.fphcare.com.

Media & Investor Contacts:

Hayden Brown
Head of Capital Markets & Investor Relations
hayden.brown@fphcare.co.nz
+64 (0) 27 807 8073
Dan Adolph
Senior Communications & Investor Relations
Manager
daniel.adolph@fphcare.co.nz
+64 (0) 22 511 4050


Authorised by Raelene Leonard, General Counsel and Company Secretary.

---

1
ASX CEO Connect conference –Fisher & Paykel Healthcare

2
Fisher & Paykel Healthcare at a glance
•Medical device manufacturer with leading positions
in respiratory care and obstructive sleep apnea
•>50 years’ experience in changing clinical practice
to solutions that provide better clinical outcomes
and improve effectiveness of care
•Estimated NZ$25+ billion and growing market
opportunity driven by demographics
•Significant organic long-term growth opportunities
in acute and chronic respiratory care, OSA and
surgery
•Large proportion (85%) of revenue from recurring
items, consumables and accessories
•High level of innovation and investment in R&D with
strong product pipeline
•High barriers to entry
Global leader in respiratory
humidification devices
Global presence
Strong financial performance
Our people
are located in
53 countries
3,538
in New Zealand
2,147
in North America,
including Mexico
379
in Europe
500
in the rest
of the world
•Continued target, and history of, doubling our
revenue (in constant currency terms) every
5 to 6 years
•Targeting gross margin of 65% and operating
margin of 30%
•Growth company with a strong history of
increasing dividend payments
Note: people numbers are represented as full-time equivalents

3
~NZ$25+ billion and growing market opportunity
HOSPITAL
HOMECARE
NEW APPLICATIONS
Applications outside of invasive ventilation
Surgical
Total addressable market estimates
~150+ million patients
~100+ million patients
Home Respiratory
Support
Obstructive Sleep
Apnea
Noninvasive
Ventilation
Invasive
Ventilation
Hospital
Respiratory Support
Infant Care
Anesthesia

4
Our progress over the last five years
FY2019FY2023ChangeComment
Countries with F&P people385339%•COVID-19 accelerated expansion
Total people4,5476,56444%
People in Manufacturing & Operations2,6803,97548%•Peaked at 4,989 in FY22
People in R&D58184646%•Accelerated R&D investment
R&D as a % of revenue9%11%165bps
Land57 ha159 ha179%•Added 102 ha for second NZ campus
Manufacturing facilities5740%•Plus preparing China and NZ5
Plant and equipment capex$41M$100M144%•Cumulative $434M over the last 5 years
Hospital hardware (% of hospital sales)12%15%300bps•Cumulative $1.2B sales over last 5 years
Patients treated with Optiflow3M out of 30M6M out of 50M100%•Peaked at 7M patients in FY21/FY22
NHF clinical practice guidelines07N /A•Guidelines for non-COVID-19 patients
NHF studies published247865250%
Anesthesiasales team2069245%•Accelerated anesthesiaopportunity

5
$0m
$100m
$200m
$300m
$400m
$500m
FY14FY15FY16FY17FY18FY19FY20FY21FY22FY23
$0.0b
$0.5b
$1.0b
$1.5b
$2.0b
FY14FY15FY16FY17FY18FY19FY20FY21FY22FY23
10-year financial summary
RevenueNet profit after tax
Hospital RevenueHomecare Revenue

6
Gross margin and operating margin targets
0%
10%
20%
30%
40%
50%
60%
70%
FY14FY15FY16FY17FY18FY19FY20FY21FY22FY23
Long Term Gross Margin target
GROSS MARGIN
0%
5%
10%
15%
20%
25%
30%
35%
40%
FY14FY15FY16FY17FY18FY19FY20FY21FY22FY23
OPERATING (EBIT) MARGIN
Long Term Operating Margin target

7
OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.
Our aspiration
The image above is an illustration of the company’s long-term growth aspirations. It is not a graph and should not be interpreted as being
indicative of levels of revenue or profitability in the short term.

8
Questions

9
Thank you